novo nordisk's semaglutide failed to slow alzheimer's disease progression Details of studies cast pall on GLP-1 as treatment Major Novo Nordisk trial finds
Description
Notably, GLP-1R is expressed in key areas of the mesolimbic system such as the ventral tegmental area, nucleus accumbens, and laterodorsal tegmental nucleus, 49 , 50 , 51 consistent with their regulation of neurobiological mechanisms that underlie the SUDs
Resetting the energy homeostasis of the brain cell
What is the key question
These medications were originally developed for the management of type 2 diabetes
How is SSK Longevity different from a med spa or telehealth service
Dangerous combination
